Skip to content
Translational Neuropharmacology Lab (Zanos Lab)

Translational Neuropharmacology Lab (Zanos Lab)

Our laboratory, based in Cyprus, employs molecular and systems neuroscience, behavioral pharmacology, as well as advanced computational methods to unravel the mysteries of brain diseases and identify targets for the development of novel and effective pharmacotherapies.

Menu
  • Home
  • News
  • Team Members
    • Lab Director
    • Current Team Members
    • Alumni
  • Research
  • Research Units
    • Translational Neuropharmacology Unit
    • Clinical Neuropsychopharmacology Unit
    • AI & Systems Bioinformatics Unit Cyprus
    • Genetic Epidemiology Unit
  • Facilities
  • Publications
  • Media
  • Join Us
  • Contact
  • More

Category: News

News

New Publication: Ketamine as a Potential Treatment for Opioid Use Disorder

No Comments
| News

The Zanos lab is excited to announce the publication of our latest research paper in the prestigious journal Biological Psychiatry. Our study explores the potential of ketamine and its metabolites as novel therapeutic strategies for treating Opioid Use Disorder (OUD). In this comprehensive review, we examine both preclinical and clinical research on ketamine’s potential in […]

Read More »

New Publication: Unveiling the Links Between Viral Infections and Alzheimer’s Disease

No Comments
| News

The Bioinformatics Unit of the Zanos Lab is proud to announce our latest publication, “From Viral Infections to Alzheimer’s Disease: Unveiling the Mechanistic Links Through Systems Bioinformatics,” which explores the complex relationship between viral infections and Alzheimer’s disease (AD). Dr. Anna Onisiforou utilized advanced systems bioinformatics techniques to investigate how various viruses, including herpesviruses, hepatitis […]

Read More »

Our postdoctoral fellow, Dr. Alexis Panutsopulos was awarded a Marie Skłodowska-Curie Young Investigator Grant (€ 147.000) for Innovative Research in the Zanos Lab

No Comments
| News

We are thrilled to announce that our postdoctoral fellow, Dr. Panutsopulos, has been awarded a Marie Skłodowska-Curie Young Investigator grant under the ONISILOS co-fund scheme. This grant  will support Dr. Panoutsopoulos’ cutting-edge research aimed at investigating the role of antidepressants, such as SSRIs and ketamine, in the development of neural tube defects (NTDs) during early […]

Read More »

Zanos Lab awarded €20,000 grant by the A. G. Leventis Foundation for our ongoing research on rapid-acting antidepressants.

No Comments
| News

We are excited to announce that the Zanos Lab has just been awarded a grant of €20,000 by the A.G. Leventis Foundation. This funding will significantly enhance our ongoing research efforts to uncover the mechanisms of action behind rapid-acting antidepressant compounds. Depression remains one of the most challenging mental health conditions, and the discovery of […]

Read More »

New article published in a Cypriot Newspaper by members of the Zanos Lab: Understanding “Smiling” Depression in the Era of Social Media

No Comments
| News

Researchers from the Zanos Lab have published an article in the Greek newspaper “Neolaia” (Youth) examining the phenomenon of “smiling” depression. This form of depression is characterized by individuals presenting a cheerful, successful image on social media while concealing their true feelings of sadness. The article, co-authored by Dr. Anna Onisiforou and Dr. Panos Zanos, […]

Read More »

Zanos laboratory’s BioNic research featured in major Cypriot newspaper: Pioneering the future of smoking cessation

No Comments
| News

The Zanos Laboratory at the University of Cyprus has recently been featured in one of Cyprus’ leading newspapers for its groundbreaking BioNic research program. Led by Principal Investigator Dr. Panos Zanos and Marie Curie fellow Dr. Andrea N. Georgiou, this innovative study aims to revolutionize smoking cessation strategies by identifying biological markers that can predict […]

Read More »

Groundbreaking Phase I clinical trial results: (2R,6R)-Hydroxynorketamine (HNK) shows excellent safety profile.

No Comments
| News

We are thrilled to announce a major milestone in our research journey. The manuscript detailing the Phase I clinical trial results for (2R,6R)-Hydroxynorketamine (HNK), a metabolite of ketamine, has just been published. The study, titled “A Phase 1 Assessment of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of (2R,6R)-HNK in healthy volunteers,” demonstrates the compound’s excellent […]

Read More »

Dr. Zanos’s Research Leads the Field in Ketamine Studies for Depression

No Comments
| News

We are proud to announce that Dr. Zanos’s groundbreaking research on ketamine has achieved exceptional recognition within the scientific community. According to a recent publication in the European Archives of Psychiatry and Clinical Neuroscience, Dr. Zanos’s work constitutes the top three most cited papers on ketamine and its enantiomers for depression from 2000 to 2023. […]

Read More »

Gut-Brain connections: Dr. Charalambous presents groundbreaking research on phageome and brain ageing at Grainau workshop

No Comments
| News

Our postdoctoral researcher Eleftheria Charalambous presented our latest findings at the 12th Grainau Workshop of Genetic Epidemiology in Grainau, Germany. With her talk “The gut phageome is associated with brain ageing” she sparked insightful conversations with other researchers. Dr. Charalambous studies the link between bacteriophages in the gut microbiome and the brain. Bacteriophages are viruses […]

Read More »

Dr. Zanos was invited as an expert to give an interview and answer critical question about depression and its underlying mechanisms by a groundbreaking European-funded initiative.

No Comments
| News

Dr. Zanos was invited as an expert contributor to the “TO AITION” project’s Q&A section. “TO AITION” is a groundbreaking EU-funded project investigating the complex relationship between cardiovascular disease (CVD) and depression, aiming to uncover underlying mechanisms and develop novel tools for prevention, diagnosis, and treatment. In this role, Dr. Zanos addressed critical questions about […]

Read More »

Posts pagination

Previous 1 … 8 9 10 … 13 Next

Recent Posts

  • New manuscript: The Immunosuppression Paradox in Multiple Sclerosis: Are We Fueling the Fire by Suppressing Immunity in an Epstein–Barr Virus–Linked Disease? March 12, 2026
  • New Preprint article – From Heatwaves to Brainwaves: Climate-Driven Microplastics Promote Epstein–Barr Virus Reactivation and Female-Biased Risk for Alzheimer’s Disease and Multiple Sclerosis February 24, 2026
  • New Publication – Linking Misophonia and Tinnitus: Common and Divergent Neurobiological Mechanisms January 29, 2026
  • Dr. Zanos Appointed to the Editorial Board of the Neuropharmacology Journal January 17, 2026
  • Zanos lab publishes a short review article on Major Depressive Disorder in Trends in Molecular Medicine January 4, 2026

Navigation

  • Home
  • News
  • Team Members
    • Lab Director
    • Current Team Members
    • Alumni
  • Research
  • Research Units
    • Translational Neuropharmacology Unit
    • Clinical Neuropsychopharmacology Unit
    • AI & Systems Bioinformatics Unit Cyprus
    • Genetic Epidemiology Unit
  • Facilities
  • Publications
  • Media
  • Join Us
  • Contact
  • More

Translational Neuropharmacology Lab (Zanos Lab) 2026 . Powered by WordPress